Lantern Pharma Executives Discuss AI's Potential to Transform CNS Oncology Drug Development
Lantern Pharma's leadership explores how artificial intelligence can significantly reduce the time and cost of developing central nervous system cancer treatments, potentially accelerating patient access to new therapies.
Lantern Pharma Inc. CEO Panna Sharma and new board member Dr. Lee Schalop recently discussed how artificial intelligence is reshaping central nervous system oncology drug development during a conversation titled "From Discovery to Clinical Trials to Patients: Key Decisions Shaping Novel CNS Oncology Medicines." The executives highlighted how Lantern's RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies, potentially revolutionizing the traditional drug development process.
Dr. Schalop, co-founder of Oncoceutics and a key figure behind the development of ONC201 (dordaviprone), reflected on lessons learned from the 16-year journey to gain approval for the H3K27M-mutant glioma treatment. This lengthy timeline exemplifies the challenges facing oncology drug development, where the path from molecule discovery to patient treatment often stretches over a decade and consumes hundreds of millions of dollars. Both leaders emphasized how AI could dramatically accelerate regulatory reviews and clinical trial design, potentially reducing these extended timelines and substantial costs.
The conversation underscored how artificial intelligence and machine learning technologies could improve patient access to new treatments by streamlining the development process. Lantern Pharma, a clinical-stage biotechnology company leveraging these technologies to redefine oncology drug development, aims to challenge conventional timelines through its AI-driven approach. The company's latest CNS cancer drug candidate, STAR-001, stands to benefit significantly from these AI-driven insights, potentially following a more efficient development pathway than traditional approaches.
Investors can access the latest news and updates relating to Lantern Pharma through the company's newsroom at https://ibn.fm/LTRN. The discussion between Sharma and Schalop represents a growing trend in biotechnology where AI platforms are being deployed to optimize drug development strategies, particularly in complex therapeutic areas like central nervous system cancers where traditional development approaches have faced significant challenges.